E. Group, Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, p.2014

G. Rosen, B. Caparros, A. Huvos, C. Kosloff, A. Nirenberg et al., Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer, pp.1221-1251, 1982.

S. Osasan, M. Zhang, F. Shen, P. Paul, S. Persad et al., Osteogenic Sarcoma: A 21st Century Review, Anticancer Research, vol.36, issue.9, pp.4391-4399, 2016.
DOI : 10.21873/anticanres.10982

S. Champiat, C. Ferté, S. Lebel-binay, A. Eggermont, and J. Soria, Exomics and immunogenics, OncoImmunology, vol.127, issue.1, p.27817, 2014.
DOI : 10.1126/scitranslmed.3003689
URL : http://www.tandfonline.com/doi/pdf/10.4161/onci.27817?needAccess=true

M. Kansara, M. Teng, M. Smyth, and D. Thomas, Translational biology of osteosarcoma, Nature Reviews Cancer, vol.34, issue.11, pp.722-757, 2014.
DOI : 10.3109/02841869509127199

B. Fritzsching, J. Fellenberg, L. Moskovszky, Z. Sápi, T. Krenacs et al., -ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study, OncoImmunology, vol.31, issue.3, p.990800, 2015.
DOI : 10.1158/1078-0432.CCR-07-4534

Y. Inagaki, E. Hookway, K. Williams, A. Hassan, U. Oppermann et al., Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours, Clinical Sarcoma Research, vol.157, issue.1, p.13, 2016.
DOI : 10.1016/S0002-9440(10)64850-X

P. Koirala, M. Roth, J. Gill, S. Piperdi, J. Chinai et al., Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res, pp.2110-2119, 2011.

M. Heymann, Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, issue.48, pp.78343-78354, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01466103

B. Ory, M. Heymann, A. Kamijo, F. Gouin, D. Heymann et al., Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer, pp.2522-2531, 2005.

J. Thiery, F. Gouin, and F. Redini, Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.

S. Piperno-neumann, L. Deley, M. Rédini, F. Pacquement, H. Marec-bérard et al., Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.8, pp.1070-80, 2016.
DOI : 10.1016/S1470-2045(16)30096-1

M. Barros, F. Hauck, J. Dreyer, B. Kempkes, and G. Niedobitek, Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages, PLoS ONE, vol.12, issue.11, p.80908, 2013.
DOI : 10.1371/journal.pone.0080908.s004
URL : https://doi.org/10.1371/journal.pone.0080908

M. Isakoff, S. Bielack, P. Meltzer, and R. Gorlick, Osteosarcoma: Current Treatment and a Collaborative Pathway to Success, Journal of Clinical Oncology, vol.33, issue.27, pp.3029-3064, 2015.
DOI : 10.1200/JCO.2014.59.4895
URL : http://europepmc.org/articles/pmc4979196?pdf=render

S. Bielack, S. Smeland, J. Whelan, N. Marina, G. Jovic et al., Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial, Journal of Clinical Oncology, vol.33, issue.20, pp.2279-87, 2015.
DOI : 10.1200/JCO.2014.60.0734

T. R?szer, Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms, Mediators of Inflammation, vol.266, issue.14, p.816460, 2015.
DOI : 10.1016/j.fsi.2013.07.042

J. Wijnen, M. Van-tol, A. Cleton-jansen, and R. Egeler, Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide incombination with interferon-?, J Exp Clin Cancer Res, vol.33, p.27, 2014.

P. Meyers, C. Schwartz, M. Krailo, J. Healey, M. Bernstein et al., Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improvesoverall survival--a report from the Children's Oncology Group, J Clin Oncol Feb, vol.126, issue.4, pp.633-641, 2008.

S. Junankar, G. Shay, J. Jurczyluk, N. Ali, J. Down et al., Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer, Cancer Discovery, vol.5, issue.1
DOI : 10.1158/2159-8290.CD-14-0621

M. Liu, L. Sun, Y. Li, H. Li, J. Zhang et al., Trastuzumab enhanced the cytotoxicity of V??9V??2 T cells against zoledronate-sensitized osteosarcoma cells, International Immunopharmacology, vol.28, issue.1, 2015.
DOI : 10.1016/j.intimp.2015.06.002

S. Sugai, T. Yoshikawa, T. Iwama, N. Tsuchiya, N. Ueda et al., Hepatocellular carcinoma cell sensitivity to V??9V??2 T lymphocyte-mediated killing is increased by zoledronate, International Journal of Oncology, vol.48, issue.5, pp.1794-804, 2016.
DOI : 10.3892/ijo.2016.3403

H. Park, H. Cho, C. Shin, H. Shon, and T. Kim, Zoledronic acid induces dose-dependent increase of antigen-specific CD8 T-cell responses in combination with peptide/poly-IC vaccine, Vaccine, vol.34, issue.10, 2016.
DOI : 10.1016/j.vaccine.2016.01.026

M. Burgess, J. Crowley, D. Reinke, R. Riedel, S. George et al., SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. Paper presented at : 2016 -American Society of Clinical Downloaded by, pp.30-54, 2017163-08.